Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical
biotechnology company with a robust pipeline of investigational
therapeutics built on protein dysregulation expertise, today
announced participation in the Alzheimer’s Association
International Conference® 2023 (AAIC®) being held July 16-20, 2023
in Amsterdam, Netherlands and virtually. Participation includes
three posters highlighting the company’s next generation therapies
for Alzheimer’s disease and a Prothena sponsored symposium.
PRX005 for the Potential Treatment of Alzheimer’s
Disease
Prothena will highlight results in a poster presentation from a
single ascending dose (SAD) study in healthy volunteers receiving
PRX005, a potentially best-in-class investigational tri-epitopic
antibody for the treatment of Alzheimer’s disease that specifically
binds with high affinity to the R1, R2, and R3 repeats within the
microtubule binding region (MTBR) of tau and targets both 3R and 4R
tau isoforms.
- Poster #74181, available to view starting Sunday, July 16,
2023
- Presenting Author: Ferenc Martényi, MD, VP, Head of
Neurodegeneration Clinical Development, Prothena
PRX123 Vaccine Candidate for the Potential Treatment and
Prevention of Alzheimer’s Disease
Prothena will present preclinical data in a late breaker poster
presentation on the immunological response to the dual Aβ/Tau
vaccine PRX123 surrogate and the effects on brain amyloid plaques
in a rapidly depositing transgenic animal model.
- Poster #82687, available to view starting Sunday, July 16,
2023
- Presenting Author: Brian Campbell, PhD, VP, Head of
Translational Medicine, Prothena
PRX012 for the Potential Treatment of Alzheimer’s
Disease
Prothena will present an encore poster presentation of data
originally presented at the 2023 International Conference on
Alzheimer’s and Parkinson’s Diseases and related neurological
disorders (AD/PD) on preclinical data from the PRX012 program
comparing a PRX012-surrogate1 (PRX012s) with lecanemab and
donanemab.
- Poster #74811, available to view starting Sunday, July 16,
2023
- Presenting Author: Brian Campbell, PhD, VP, Head of
Translational Medicine, Prothena
Prothena Sponsored Symposium
On Tuesday, July 18 from 5:45-7:45 PM CEST, Prothena will host
an industry sponsored symposium titled “The Voice of the Patient
with AD: What Progress in AD Treatment Means to People Living with
the Disease”.
About PRX005
PRX005 is designed to be a best-in-class anti-tau antibody that
specifically binds with high affinity to the R1, R2, and R3 repeats
within the MTBR of tau and targets both 3R and 4R tau isoforms.
MTBR tau has been shown in preclinical studies to be involved in
the pathological spread of tau. Neurofibrillary tangles composed of
misfolded tau proteins, along with amyloid beta plaques, are
pathological hallmarks of Alzheimer’s disease. Cell-to-cell
transmission of pathogenic extracellular tau and the accumulation
of pathogenic tau also correlate with the progression of
symptomatology and clinical decline in patients with Alzheimer’s
disease. Recent publications suggest that during the course of
Alzheimer’s disease progression, tau appears to spread throughout
the brain via synaptically-connected pathways; this propagation of
pathology is thought to be mediated by tau “seeds” containing the
MTBR of tau. Additionally, it has been recently reported that the
presence of MTBR fragments in cerebrospinal fluid correlate with
dementia stages and tau tangles in Alzheimer’s disease to a higher
degree than fragments of other tau regions. In preclinical
research, antibodies targeting this region of tau were superior in
blocking tau uptake and neurotoxicity, which has been associated
with efficacy in Alzheimer’s disease animal models. In these
preclinical models, PRX005 demonstrated significant reduction of
intraneuronal tau pathology and protection against behavioral
deficit in a tau transgenic mouse model and complete blockade of
neuronal tau internalization in vitro.
About PRX123
PRX123, a potential first-in-class dual Aβ/tau vaccine, was
designed for the treatment and prevention of Alzheimer's disease
and is a dual-target vaccine targeting key epitopes within the
N-terminus of Aβ and MTBR-tau to simultaneously promote amyloid
clearance and blockade of pathogenic tau.
About PRX012
PRX012, an investigational next-generation anti-Aβ antibody, was
designed as a subcutaneous IgG1 mAb to target aggregated forms of
Aβ, including protofibrils and plaques, with high binding affinity.
PRX012 is currently being investigated in a Phase 1 clinical study
for the treatment of Alzheimer’s disease. Preclinical data have
demonstrated binding of PRX012 to beta amyloid plaques and
oligomers with high affinity, allowing effective Aβ plaque
occupancy and removal at relatively lower dose ranges, optimal for
subcutaneous delivery. Preclinical data have also demonstrated
clearance of both pyroglutamate modified and unmodified Aβ plaque
in brain tissue at concentrations of PRX012 estimated to be
clinically achievable in the central nervous system with
subcutaneous delivery.
About Alzheimer’s Disease
Alzheimer’s disease is a fatal disease and the most common form
of dementia causing increasingly serious symptoms, including
confusion, disorientation, mood and behavioral changes, and
difficulty speaking, swallowing, and walking. Approximately 55
million people worldwide are estimated to be living with
Alzheimer’s disease or other dementias. Alzheimer’s disease is the
most common neurodegenerative disorder. There is an urgent need for
therapies that slow the progression and ultimately prevent
Alzheimer’s disease to address this global healthcare crisis.
Prothena’s Alzheimer’s disease portfolio spans next generation
antibody immunotherapy, small molecule, and vaccine approaches,
geared toward building upon first generation treatments to advance
the treatment paradigm.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology
company with expertise in protein dysregulation and a pipeline of
investigational therapeutics with the potential to change the
course of devastating neurodegenerative and rare peripheral amyloid
diseases. Fueled by its deep scientific expertise built over
decades of research, Prothena is advancing a pipeline of
therapeutic candidates for a number of indications and novel
targets for which its ability to integrate scientific insights
around neurological dysfunction and the biology of misfolded
proteins can be leveraged. Prothena’s pipeline includes both
wholly-owned and partnered programs being developed for the
potential treatment of diseases including AL amyloidosis, ATTR
amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number
of other neurodegenerative diseases. For more information, please
visit the Company’s website at www.prothena.com and follow the
Company on Twitter @ProthenaCorp.
Forward-Looking Statements
This press release contains forward-looking statements. These
statements relate to, among other things, the treatment potential,
designs, proposed mechanisms of action, and potential
administration of PRX005, PRX012, and PRX123. These statements are
based on estimates, projections and assumptions that may prove not
to be accurate, and actual results could differ materially from
those anticipated due to known and unknown risks, uncertainties and
other factors, including but not limited to those described in the
“Risk Factors” sections of our Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission (SEC) on May 4, 2023,
and discussions of potential risks, uncertainties, and other
important factors in our subsequent filings with the SEC. We
undertake no obligation to update publicly any forward-looking
statements contained in this press release as a result of new
information, future events, or changes in our expectations.
_____________________________ 1 “Surrogate” is defined as an
antibody with >99.5% homology, the same binding epitope and
equivalent binding profile to different forms of Aβ where directly
compared.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230711184037/en/
Media and Investor Contact:
Media Michael Bachner, Senior Director, Corporate Communications
609-664-7308, michael.bachner@prothena.com
Investors Mark Johnson, CFA, Vice President, Investor Relations
650-417-1974, mark.johnson@prothena.com
Prothena (NASDAQ:PRTA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Prothena (NASDAQ:PRTA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024